Acute leukemia evolving from multiple myeloma and co‐expressing myeloid and plasma cell antigens

Stewart, A. Keith; Freedman, Jason L.; Garvey, M. B.

doi:10.1002/ajh.2830340311

Cited by 5 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A identificação imunofenotípica de múltiplas linhagens nas células mielomatosas nos faz concluir que a origem mais provável desta patologia seja uma célula progenitora pluripotente (8,18). A marcação fenotípica das células mielomatosas na medula óssea revela a expressão de antígenos mielóides/monocíticos (CD11b, CD13, CD14, CD15, CD33), antígenos linfóides de linhagens T e B (CD2, CD4, CD5, CD7, CD10, PCA-1), antígenos associados aos linfócitos natural killer (CD56), antígenos associados a células precursoras (HLA-DR) e antígenos associados a proliferação (CD25, CD38) (11,12).…”

Section: Jornal Brasileiro De Patologia E Medicina Laboratorial Discuunclassified

A importância da citometria de fluxo no diagnóstico raro de mieloma mielomonocítico

Bacal¹,

Guerra²,

Ferreira³

et al. 2002

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

Section: Jornal Brasileiro De Patologia E Medicina Laboratorial Discuunclassified

A importância da citometria de fluxo no diagnóstico raro de mieloma mielomonocítico

Bacal¹,

Guerra²,

Ferreira³

et al. 2002

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma

et al. 1993

View full text Add to dashboard Cite

CD16, the type III receptor for IgG, is expressed on neutrophils, natural killer cells, and some T lymphocytes, mast cells, and activated monocytes but not on cells of the B-lymphocyte lineage including plasma cells. It is also produced in a soluble form found in serum. We analyzed sera from 165 multiple-myeloma patients, 29 patients with monoclonal gammopathies of unknown significance, and 20 normal disease-free donors. We found that the level of soluble CD16 was significantly decreased in sera from patients with multiple myeloma compared to sera from healthy and monoclonal gammopathies of unknown significance donors (P = 0.0001). In addition, a stage-dependent decrease in soluble CD16 was observed, with a highly significant difference (P = 0.004) between stage I and stage II+III myeloma patients. The correlation between the myeloma stage and the serum level of soluble CD16, which is related to the host response, was found to be more sensitive than that of beta 2-microglobulin, which reflects the tumor burden. The concomitant evaluation of the serum levels of these two markers allows better staging and therefore has a more precise prognostic value.

show abstract

Acute Promyelocytic Leukaemia Complicating Multiple Myeloma: Evidence of Different Cell Lineages

Dunkley¹,

Gibson²,

Iland³

et al. 1999

Leukemia & Lymphoma

View full text Add to dashboard Cite

The association of leukemia and multiple myeloma is well described usually as a complication of chemotherapy but also in the absence of chemotherapy or at diagnosis. Such leukemias are typically acute myeloid leukemia (AML), particularly myelomonocytic subtype, and cases of acute promyelocytic leuke (APL) are rarely reported. Controversy exists as to whether myeloma and AML originate from a single haematopoietic progenitor or arise from different cell lineages. We report a case of a 58 year old female who developed APL 10 months following diagnosis of nonsecretory light chain (kappa) myeloma which had been treated with local spinal irradiation and low dose oral melphalan and prednisone. Clonality had originally been demonstrated by light chain restriction (kappa) of her bone marrow plasma cells whilst immunoglobulin heavy chain and T cell receptor genes were germ line. At development of APL cytogenetics revealed t(15;17) and PML-RAR fusion gene was detected by RT-PCR. The patient was treated with all-trans retinoic acid (ATRA) and received 2 cycles of consolidation chemotherapy with Idarubicin. Following this therapy the t(15;17) and PML-RAR were both undetectable whilst the clonal population of kappa staining plasma cells persisted. This particular patient represents a rare case of APL complicating multiple myeloma with persistence of the myeloma clone but disappearance of PML-RAR alpha RNA following therapy. This case study appears to support the argument that the APL and myeloma originated from distinct cell lineages.

show abstract

Acute leukemia evolving from multiple myeloma and co‐expressing myeloid and plasma cell antigens

Cited by 5 publications

References 16 publications

A importância da citometria de fluxo no diagnóstico raro de mieloma mielomonocítico

A importância da citometria de fluxo no diagnóstico raro de mieloma mielomonocítico

Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma

Acute Promyelocytic Leukaemia Complicating Multiple Myeloma: Evidence of Different Cell Lineages

Contact Info

Product

Resources

About